Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Revenue grew by 461% year over year. However, EPS missed estimates. It is growing extremely fast and organic growth is forecasted to be driven by partner relationships. The balance sheet is growing rapidly and top-line growth should outpace operating expenses. Unlock Premium - Try 5i Free
CloudMD is a Canadian stock, trading under the symbol DOC-X on the TSX Venture Exchange (DOC-CV). It is usually referred to as TSXV:DOC or DOC-X
In the last year, 5 stock analysts published opinions about DOC-X. 4 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for CloudMD.
CloudMD was recommended as a Top Pick by on . Read the latest stock experts ratings for CloudMD.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
5 stock analysts on Stockchase covered CloudMD In the last year. It is a trending stock that is worth watching.
On 2023-03-24, CloudMD (DOC-X) stock closed at a price of $0.18.
Tele-health company.
Has sold shares. Very high valuations.
Path to profitability slower than expected.
Recently selling assets.
Not sure path to profitability.